Estrella Immunopharma

ESLANasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$21.096 M

$0.49 -3.42%

Close of 22 Sept 2026

Revenue

—

Not reported

Earnings

-$13.1M

Loss-making

Shares outstanding

43,497,864

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Other share classes

Estrella Immunopharma lists more than one class of stock. Company figures above cover all classes combined.

ESLAW

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 160 →

#139Evaxion A/SEVAX$29.5M
#140TScan TherapeuticsTCRX$22.5M
#141Estrella ImmunopharmaESLA$21.1M
#142Jasper TherapeuticsJSPR$20.7M
#143Dyadic InternationalDYAI$16.0M

What if Estrella Immunopharma were worth as much as…

Open the what-if tool →

Gold $30.2T

$695,067.92

Per share 1,433,130× higher

Bitcoin $1.74T

$40,040.01

Per share 82,557× higher

Nvidia $5.52T

$126,805.47

Per share 261,455× higher

Or at a round number

$50.0M $100.0M $200.0M $500.0M

Where these numbers come from

Share counts and financials for Estrella Immunopharma are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 23 Sept 2026. Read the methodology.